QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
TSE:ONC

Oncolytics Biotech (ONC) Stock Forecast, Price & News

C$2.11
-0.04 (-1.86%)
(As of 06/6/2023 ET)
Compare
Today's Range
C$2.10
▼
C$2.21
50-Day Range
C$1.51
▼
C$2.93
52-Week Range
C$1.06
▼
C$3.10
Volume
87,734 shs
Average Volume
56,053 shs
Market Capitalization
C$135.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$6.75
ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial Media

Oncolytics Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
219.9% Upside
C$6.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.38mentions of Oncolytics Biotech in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

See Top Rated MarketRank™ Stocks Here

ONC stock logo

About Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONC Stock News Headlines

June 5, 2023 | finanznachrichten.de
FinancialNewsMedia.com: Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
June 5, 2023 | finance.yahoo.com
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate
June 6, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
June 4, 2023 | americanbankingnews.com
Oncolytics Biotech (TSE:ONC) Stock Crosses Above Two Hundred Day Moving Average of $2.12
May 31, 2023 | baystreet.ca
Significant Oncology Results Set to be Delivered as Oral Presentations at ASCO 2023
May 27, 2023 | americanbankingnews.com
Oncolytics Biotech (TSE:ONC) PT Set at C$9.00 by Jonestrading
May 26, 2023 | msn.com
Oncolytics Biotech Dives after Breast Cancer Treatment Disappoints
May 26, 2023 | msn.com
Oncolytics falls 16% after mid-stage data for breast cancer therapy
June 6, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
May 26, 2023 | finanznachrichten.de
USA News Group: Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations
May 25, 2023 | finance.yahoo.com
Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract
May 24, 2023 | finance.yahoo.com
CANADA STOCKS-TSX tumbles as bank earnings, US debt deal uncertainty weigh
May 24, 2023 | baystreet.ca
TSX Sinks into the Red
May 24, 2023 | benzinga.com
Oncolytics Biotech shares are trading higher after JonesTrading initiated covered on the stock with a Buy rating and announced a $9 price target.
May 21, 2023 | americanbankingnews.com
Oncolytics Biotech (TSE:ONC) Stock Price Passes Above Two Hundred Day Moving Average of $2.09
May 13, 2023 | americanbankingnews.com
FY2027 EPS Estimates for Oncolytics Biotech Inc. (TSE:ONC) Increased by Analyst
May 12, 2023 | americanbankingnews.com
Q2 2023 Earnings Forecast for Oncolytics Biotech Inc. (TSE:ONC) Issued By HC Wainwright
May 10, 2023 | finanznachrichten.de
Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
May 9, 2023 | markets.businessinsider.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY) and Senseonics Holdings (SENS)
May 7, 2023 | finance.yahoo.com
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2023 Earnings Call Transcript
May 6, 2023 | ca.finance.yahoo.com
Stocks in play: Oncolytics Biotech
May 5, 2023 | benzinga.com
Oncolytics Biotech Says Cash Balance Of C$29.7M Is Expected To Provide Projected Cash Runway For At Least 12 Months
May 5, 2023 | msn.com
Oncolytics Biotech: Q1 Earnings Insights
May 5, 2023 | finance.yahoo.com
Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights
May 4, 2023 | americanbankingnews.com
Oncolytics Biotech (ONC) Set to Announce Quarterly Earnings on Friday
May 3, 2023 | marketwatch.com
Oncolytic Virus Therapy Market : Competitive Strategy Analysis and Forecast Values 2023-2031
April 27, 2023 | marketwatch.com
Global Oncolytic Virus Therapy Market by [2023-2029] with Revenue Outsourcing
See More Headlines

ONC Price History

ONC Company Calendar

Today
6/06/2023
Next Earnings (Estimated)
8/10/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
TSE:ONC
CUSIP
N/A
CIK
N/A
Web
www.oncolyticsbiotech.com
Phone
+1-403-6707380
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$6.75
High Stock Price Forecast
C$9.00
Low Stock Price Forecast
C$3.00
Forecasted Upside/Downside
+209.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
C($0.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-24,490,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-80.61%
Return on Assets
-42.85%

Debt

Debt-to-Equity Ratio
2.20
Current Ratio
13.88
Quick Ratio
8.86

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$0.52 per share
Price / Cash Flow
4.22
Book Value
C$0.40 per share
Price / Book
5.45

Miscellaneous

Outstanding Shares
64,090,000
Free Float
N/A
Market Cap
C$139.72 million
Optionable
Not Optionable
Beta
1.79

Key Executives

  • Dr. Matthew C. Coffey M.B.A.
    Ph.D., Pres, CEO & Director
  • Mr. Kirk J. Look C.A.
    CA, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro (Age 55)
    Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc
    Comp: $558.94k
  • Dr. Thomas C. Heineman M.D.
    Ph.D., Chief Medical Officer
  • Ms. Allison Hagerman P.Eng.
    P.M.P., VP of Product Devel.
  • Jon Patton
    Director of Investor Relations & Communication
  • Dr. Grey Wilkinson Ph.D.
    Scientist of Translational Medicine
  • Mr. John Mark Lievonen F.C.A.
    FCA, Consultant
  • Dr. Daniel Douglas Von Hoff F.A.C.P. (Age 74)
    FACP, M.D., Consultant

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













ONC Stock - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ONC shares.
View ONC analyst ratings or view top-rated stocks.

What is Oncolytics Biotech's stock price forecast for 2023?

5 equities research analysts have issued 1 year price targets for Oncolytics Biotech's stock. Their ONC share price forecasts range from C$3.00 to C$9.00. On average, they expect the company's stock price to reach C$6.75 in the next year. This suggests a possible upside of 209.6% from the stock's current price.
View analysts price targets for ONC or view top-rated stocks among Wall Street analysts.

How have ONC shares performed in 2023?

Oncolytics Biotech's stock was trading at C$2.22 at the beginning of the year. Since then, ONC shares have decreased by 1.8% and is now trading at C$2.18.
View the best growth stocks for 2023 here.

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ONC earnings forecast.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR).

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

How do I buy shares of Oncolytics Biotech?

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Oncolytics Biotech's stock price today?

One share of ONC stock can currently be purchased for approximately C$2.18.

How much money does Oncolytics Biotech make?

Oncolytics Biotech (TSE:ONC) has a market capitalization of C$139.72 million. The company earns C$-24,490,000.00 in net income (profit) each year or C($0.42) on an earnings per share basis.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The official website for the company is www.oncolyticsbiotech.com. The company can be reached via phone at +1-403-6707380.

This page (TSE:ONC) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -